Kathmandu. China’s National Medical Products Administration (NMPA) and the National Health Service Security Administration have launched joint investigations of medical institutions and drug wholesalers in the Inner Mongolia Autonomous Region and Shaanxi Province after identifying suspicious activity through drug traceability code screening.
According to a report in China Daily, the investigation will focus on irregularities in medical insurance fund management and drug distribution supply chains. That includes unusual traceability records and questionable fake reimbursement claims.
According to officials, any violations discovered during the investigation will be dealt with in accordance with the law. “There is a need to strengthen the nationwide drug traceability system to protect drug quality and safety,” NMPA said. Widespread adoption of digital tracking technology and better coordination among government agencies will help detect irregularities and enhance regulatory oversight. ’
